Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
Literatur
1
Sølling AS,
Harslof T,
Langdahl B.
Treatment with zoledronate subse-quent to denosumab in osteoporosis: a
randomized trial. J BoneMiner Res 2020; 35: 1858-1870
2
Sølling AS,
Harsløf T,
Langdahl B.
Treatment with zoledronate subse-quent to denosumab in osteoporosis: a 2-year
randomized study. J Bone Miner Res 2021; 36: 1245-1254
3
Tsourdi E,
Zillikens MC,
Meier C.
et al. Fracture risk and managementof discontinuation of denosumab therapy: a
systematic review andposition statement by ECTS. J Clin Endocrinol Metab 2021; 106: 264-281
4
Kendler D,
Chines A,
Clark P.
et al. Bone mineral density after transi-tioning from denosumab to alendronate. J Clin Endocrinol Metab 2020; 105: e255-e264
5
Simpson EL,
Martyn-St James M,
Hamilton J,
Wong R,
Gittoes N,
Selby P,
Davis S.
Clinical effectiveness of denosumab, raloxifene, romosozumab, and teriparatide
for the prevention of osteoporotic fragility fractures: a systematic review and
network meta-analysis. Bone 2020; 130: 115081
6
Chotiyarnwong P,
McCloskey E,
Eastell R,
McClung MR,
Gielen E,
Gostage J,
Cummings SR.
A pooled analysis of fall incidence from placebo-controlled trials of
denosumab. Journal of bone and mineral research 2020; 35: 1014-1021
7
Larsson BAM,
Johansson L,
Johansson H,
Axelsson KF,
Harvey N.
et al. The timed up and go test predicts fracture risk in older women independently of
clinical risk factors and bone mineral density. Osteoporosis International 2021; 32: 75-84
8
Zhu K,
Devine A,
Lewis JR,
Dhaliwal SS,
Prince RL.
'Timed up and go' test and bone mineral density measurement for
fracture prediction. Arch Intern Med 2011; 171: 1655-1661
9
Miedany YE,
Gaafary ME,
Toth M,
Hegazi MO,
Aroussy NE,
Hassan W,
Galal S.
Is there a potential dual effect of denosumab for treatment of osteoporosis and
sarcopenia?. Clinical Rheumatology 2021; 40: 4225-4232
